[go: up one dir, main page]

CL2004001272A1 - COMPOUNDS DERIVED FROM 3- (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) -1,1-DISUSTITUDE-UREA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF THE COMPOUND IN THE TREATMENT OF RELATED DISEASES CO - Google Patents

COMPOUNDS DERIVED FROM 3- (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) -1,1-DISUSTITUDE-UREA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF THE COMPOUND IN THE TREATMENT OF RELATED DISEASES CO

Info

Publication number
CL2004001272A1
CL2004001272A1 CL200401272A CL2004001272A CL2004001272A1 CL 2004001272 A1 CL2004001272 A1 CL 2004001272A1 CL 200401272 A CL200401272 A CL 200401272A CL 2004001272 A CL2004001272 A CL 2004001272A CL 2004001272 A1 CL2004001272 A1 CL 2004001272A1
Authority
CL
Chile
Prior art keywords
compound
treatment
disustitude
benzotiazol
morfolin
Prior art date
Application number
CL200401272A
Other languages
Spanish (es)
Inventor
Flohr Roland Jakob-R Alexander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2004001272A1 publication Critical patent/CL2004001272A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CL200401272A 2003-05-30 2004-05-26 COMPOUNDS DERIVED FROM 3- (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) -1,1-DISUSTITUDE-UREA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF THE COMPOUND IN THE TREATMENT OF RELATED DISEASES CO CL2004001272A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03012118 2003-05-30

Publications (1)

Publication Number Publication Date
CL2004001272A1 true CL2004001272A1 (en) 2005-04-22

Family

ID=33442738

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401272A CL2004001272A1 (en) 2003-05-30 2004-05-26 COMPOUNDS DERIVED FROM 3- (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) -1,1-DISUSTITUDE-UREA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF THE COMPOUND IN THE TREATMENT OF RELATED DISEASES CO

Country Status (27)

Country Link
US (1) US7285548B2 (en)
EP (1) EP1633355B1 (en)
JP (1) JP4426572B2 (en)
KR (1) KR100765566B1 (en)
CN (1) CN1798558B (en)
AR (1) AR044569A1 (en)
AT (1) ATE396726T1 (en)
AU (1) AU2004243481B2 (en)
BR (1) BRPI0410878A (en)
CA (1) CA2527174C (en)
CL (1) CL2004001272A1 (en)
DE (1) DE602004014138D1 (en)
DK (1) DK1633355T3 (en)
ES (1) ES2307015T3 (en)
HR (1) HRP20080318T3 (en)
IL (1) IL171769A (en)
MX (1) MXPA05012772A (en)
MY (1) MY138018A (en)
NO (1) NO20055176L (en)
NZ (1) NZ543372A (en)
PL (1) PL1633355T3 (en)
PT (1) PT1633355E (en)
RU (1) RU2348629C2 (en)
SI (1) SI1633355T1 (en)
TW (1) TW200508230A (en)
WO (1) WO2004105755A1 (en)
ZA (1) ZA200509608B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369256T3 (en) * 2000-06-26 2011-11-28 Helen Of Troy Limited RECHARGEABLE LAMP SYSTEM.
CN1989117B (en) * 2004-07-22 2011-01-19 弗·哈夫曼-拉罗切有限公司 Substituted benzothiazoles
US8247609B2 (en) * 2005-10-25 2012-08-21 Pharamleads Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors
GB0622826D0 (en) * 2006-11-15 2006-12-27 Acurepharma Ab Novel amides acting on the adenosine receptors
WO2010140339A1 (en) * 2009-06-01 2010-12-09 武田薬品工業株式会社 Heterocyclic compound
CA2892899C (en) 2012-12-21 2021-07-20 Janssen Sciences Ireland Uc Antibacterial compounds
DE102019110904B4 (en) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)acetamide derivatives and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8181701A (en) * 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
HRP20080318T3 (en) 2008-07-31
ZA200509608B (en) 2007-04-25
WO2004105755A1 (en) 2004-12-09
US7285548B2 (en) 2007-10-23
ATE396726T1 (en) 2008-06-15
US20040242576A1 (en) 2004-12-02
AU2004243481B2 (en) 2008-10-09
SI1633355T1 (en) 2008-08-31
NZ543372A (en) 2008-11-28
RU2348629C2 (en) 2009-03-10
DK1633355T3 (en) 2008-08-04
DE602004014138D1 (en) 2008-07-10
TW200508230A (en) 2005-03-01
JP2006526003A (en) 2006-11-16
AU2004243481A1 (en) 2004-12-09
RU2005141307A (en) 2006-07-27
NO20055176L (en) 2005-11-03
BRPI0410878A (en) 2006-07-04
CN1798558B (en) 2012-09-05
CN1798558A (en) 2006-07-05
MY138018A (en) 2009-04-30
PT1633355E (en) 2008-07-15
ES2307015T3 (en) 2008-11-16
IL171769A (en) 2010-12-30
CA2527174C (en) 2014-03-25
KR100765566B1 (en) 2007-10-09
EP1633355A1 (en) 2006-03-15
CA2527174A1 (en) 2004-12-09
MXPA05012772A (en) 2006-02-13
PL1633355T3 (en) 2008-10-31
JP4426572B2 (en) 2010-03-03
AR044569A1 (en) 2005-09-21
EP1633355B1 (en) 2008-05-28
KR20060032955A (en) 2006-04-18

Similar Documents

Publication Publication Date Title
CL2004001069A1 (en) COMPOUNDS DERIVED FROM 1-BENZOIL-ISOQUINOLINAS SUBSTITUTED; PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PROFILAXIS OF TYPE II DIABETES.
LTC1781298I2 (en) Pharmaceutical compositions containing benzoxazine for the treatment of respiratory diseases
CL2007000806A1 (en) COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007001993A1 (en) COMPOUNDS DERIVED FROM HYDROXYLATED AND METOXYLATED PYRIMIDILCICLOPENTANOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF AN INFLAMMATORY, HYPERPROLIFERANT, CARDIOVASCULAR, NEURODEGENERAT DISEASE
CL2007002207A1 (en) COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.
CL2004000234A1 (en) DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
CL2007001918A1 (en) SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
CL2007002327A1 (en) COMPOUNDS DERIVED FROM REPLACED FENIL-IMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF HCV.
CL2004000788A1 (en) COMPOUNDS DERIVED FROM N- [2-OXO-6- (ARIL OR HETEROARIL) AZEPAN-3-IL] -4- (2-OXO-2,3-DIHIDRO-1H-IMIDAZO [4,5-B] PIRIDIN-1 -IL) PIPERIDINE-1-CARBOXAMIDE, ANTIGONISTS OF CGRP RECEPTORS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF D
NO2014009I2 (en) Compounds, pharmaceutical compositions and uses thereof, and process for the preparation of said compounds
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
CL2003002287A1 (en) COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
CL2007002610A1 (en) COMPOUNDS DERIVED FROM REPLACED BIPIRIDINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS HYPERTONIA, DIABETES, MYOCARDIAL INFARTS, BETWEEN OTHERS.
CL2003002353A1 (en) COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
CL2008001122A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2,3-IJ] -1,8-NAFTIRIDIN-4,9-DIONA; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF BACTERIAL INFECTIONS.
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
CL2009000200A1 (en) Compounds derived from 2,7-naphthyridines-1-one, mediators of syk; pharmaceutical composition; and use in the treatment of inflammatory, respiratory, cellular proliferative or autoimmune disease.
CL2008002353A1 (en) COMPOUNDS DERIVED FROM 7H-INDOLO [2,1-A] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF HEPATITIS C.
ITMI20031570A1 (en) COMPOSITION FOR DIETARY, PHARMACEUTICAL OR COSMETIC USE
CL2007002619A1 (en) COMPOUNDS DERIVED FROM 3-AZA-BICICLO [4.1.0] HEPTANO; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DEPRESSION.
CY2018006I2 (en) THERAPEUTIC FORMULATION OF CLADRIVINE FOR THE THERAPEUTIC TREATMENT OF PLAQUE STICHERONE
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
CL2007003672A1 (en) COMPOUNDS DERIVED FROM HETEROARIL-PIRROLIDINIL-CETONA AND HETEROARIL-PIPERIDINIL-CETONA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DEPRESSION AND ANXIETY.
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.